Overview

This trial is active, not recruiting.

Condition breast cancer
Treatment interstitial implant brachytherapy
Phase phase 1/phase 2
Sponsor Massachusetts General Hospital
Start date June 1997
End date May 2001
Trial size 45 participants
Trial identifier NCT00977275, 97-585

Summary

The purpose of this study is to evaluate radiation therapy directed to a small region of the breast in women who were recently diagnosed with early stage invasive breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
To determine if interstitial implant brachytherapy to radical radiation doses is feasible following wide local excision of T1N0 breast carcinoma
time frame: 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Low risk of multifocal disease within the breast whose tumor location is favorable for brachytherapy catheter placement - Diagnosis of invasive breast carcinoma (biopsy or fine needle aspiration cytology) and be clinical stage T1N0 (primary tumor < 2cm, clinically negative nodes) - Location of primary tumor is not immediately adjacent to the nipple of chest wall - No evidence of two or more separate tumors within the breast - All histologic types and pathologic grades of primary tumor - No extensive intraductal component (substantial intraductal carcinoma away from the primary tumor location) - No lymphatic or vascular invasion - Lymph node staging by sentinel node excision or axillary dissection confirms node negative status (If node positive, implant is used to deliver boost to tumor bed) - Assessment of final surgical margins should be predominantly negative, but a single small region of focal positivity is allowable as it is for whole breast radiation - 18 years of age or older Exclusion Criteria: - Tumor is too close to the chest wall to allow placement of catheters - Contraindications to radiation therapy are present, including a history of scleroderma, systemic lupus or other active connective tissue disease, pregnancy, or prior chest wall radiation

Additional Information

Official title The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant
Principal investigator Alphonse Taghian, MD, PhD
Description - When participants undergo surgery to remove the tumor (lumpectomy), it will be followed by the placement of small flexible tubes throughout the region surrounding the site of operation. These tubes will remain in place for 7-9 days following the surgery. - The first 2-3 days, the tubes will not contain radioactivity. This time is used to do all the calculations necessary for treatment and to check the findings in the breast tissue that was removed. After 2-3 days, the tubes will be filled with a radioactive wire which will remain in place for the next 5 days. During this period of time, participants will be required to remain within the hospital. At the end of these 5 days, the radioactive wires and tubes will be removed.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Massachusetts General Hospital.